Navigation Links
Dynavax Presents New Analysis of TOLAMBA(TM) Data at ACAAI Meeting
Date:11/12/2007

for this finding."

The multi-center DARTT study was comprised of 738 subjects with ragweed allergic rhinitis, including 241 placebo subjects. A positive skin test to ragweed was required for enrollment in the study. On January 8, 2007, Dynavax reported that the placebo group overall did not demonstrate sufficient levels of ragweed allergic rhinitis and as a result, no meaningful clinical effect could be measured.

Abstract #31 (ID 385836) entitled, "Wheal and erythema to ragweed extract are distinct predictors of symptom scores in ragweed allergic patients," was part of Concurrent Session "D" on Immunotherapy and Pharmacology.

About TOLAMBA

TOLAMBA consists of Dynavax's proprietary immunostimulatory sequences (ISS) linked to the purified major allergen of ragweed, called Amb a 1. TOLAMBA is designed to target the underlying cause of seasonal allergic rhinitis caused by ragweed. The linking of ISS to Amb a 1 ensures that both ISS and ragweed allergen are presented simultaneously to the same immune cells, producing a highly specific and potent inhibitory effect and suppressing the Th2 cells responsible for inflammation associated with ragweed allergy.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV(TM), a hepatitis B vaccine in Phase 3 partnered with Merck & Co. Inc.; TOLAMBA, a ragweed allergy immunotherapy in Phase 2; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; an
'/>"/>

SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
2. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Perrigo Company (NYSE: ... has received an AB therapeutic equivalent rating from the ... approved New Drug Application (NDA) for testosterone gel 1.0%. ... to [AbbVie,s] AndroGel 1% and can be substituted with ... clinical effect and safety profile as AndroGel 1% when ...
(Date:7/24/2014)... KIRKLAND, Wash. , July 24, 2014 ... exhibiting at the 2014 National Association of State Veterans ... Carolina . The goal of the NASVH is ... receives the benefits, services, long term health care and ... sacrifice. With the InSite® Remote Dispensing ...
(Date:7/24/2014)... , July 24, 2014  Lazarus Effect, a ... novel interventional devices to facilitate removal of blood ... and Trademark Office has issued a new patent ... the company,s Lazarus Cover TM and ReCover ... ReCover is a single-component stent-retriever (stentriever) with an ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
... YORK, Dec. 5, 2010 Pfizer Inc. (NYSE: ... Directors has elected Ian C. Read, 57, currently head ... Executive Officer and Director. Mr. Read succeeds Jeffrey B. ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) The Board,s Lead Independent ...
Cached Medicine Technology:ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4
(Date:7/24/2014)... Voted one of the most reliable online dress suppliers ... providing its new and old customers with the latest ... announced its new collection of high end wedding dresses. ... to the latest fashion trends. Additionally, they are now ... As a matter of fact, high end special occasion ...
(Date:7/24/2014)... 2014 The federal judge overseeing ... in the U.S. District Court, District of Massachusetts, ... medical information covered by the federal Health Insurance ... 16th Order, U.S. District Judge Douglas P. Woodlock ... Care the right to receive HIPAA- protected information. ...
(Date:7/24/2014)... 24, 2014 CarePoint Health is ... hematology and oncology, Dr. Hitendra Upadhyaya, has joined ... welcomes Dr. Upadhyaya to the community. Hundreds of ... Medical Group, a comprehensive network of top doctors ... range of specialties. This latest acquisition represents CarePoint ...
(Date:7/24/2014)... treatment of overweight and obese preschoolers works better when ... only the child is targeted, according to research published ... the University at Buffalo and Women and Children,s Hospital ... or obese and had one parent who participated in ... to body mass index (BMI) measurements, calculated based on ...
(Date:7/24/2014)... between two or more equally positive outcomes experience ... with activity in different regions of the brain, ... associate research scholar at the Princeton Neuroscience Institute ... 42 people rated the desirability of more than ... looked at images of paired products with different ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3
... ... since 1998, has now processed 1.5 million orders. The website provides lifestyle medications such as ... that is reviewed by a U.S.-licensed doctor. Visitors do not need to have a prescription ... ...
... ... Law & Technology,s information privacy programs and senior fellow to the Samuelson Law, Technology & ... Ad Ops Forum taking place in San Francisco on June 17. , ... (PRWEB) May 18, 2010 -- Chris Jay Hoofnagle, ...
... , ... consultancy providing unique IT solutions for the healthcare industry, announces a new whitepaper on the ... ... -- Arcadia Solutions , a national consultancy providing unique IT solutions for the healthcare ...
... ... on the ten distinct warning signs that foretell violence and the appropriate responses. “Workplace ... approaching the subject directly and honestly. , ... (PRWEB) May 18, 2010 -- Kantola Productions LLC has released ...
... effective way to convince young women to cut back on ... melanoma, the deadliest form of skin cancer, by 75 percent? ... "They,re not worried about skin cancer, but they are ... a professor of dermatology at Northwestern University Feinberg School of ...
... than thought, says a University of Florida researcher about a ... could lead to identifying those at risk for developmental disorders ... form of learning in sleeping newborns, a type of learning ... Byrd, a research affiliate in psychology at UF who collaborated ...
Cached Medicine News:Health News:Safe & Secure Online Pharmacy Viamedic.com; Reaches Milestone of 1.5 Million Orders Processed 2Health News:Chris Jay Hoofnagle to Deliver Keynote at the AdMonsters US Network Ad Ops Forum II, June 17, San Francisco 2Health News:Chris Jay Hoofnagle to Deliver Keynote at the AdMonsters US Network Ad Ops Forum II, June 17, San Francisco 3Health News:How Health Plans Can Turn Customer Touch Points into a Competitive Advantage – Whitepaper Release 2Health News:Kantola Productions Releases Workplace Violence Prevention Training Video 2Health News:Wrinkles are scarier than skin cancer for young tanners 2Health News:Wrinkles are scarier than skin cancer for young tanners 3Health News:Newborn infants learn while asleep; study may lead to later disability tests 2
... V is a low viscosity bone cement, ... vertebroplasty. The bone cement is injected into ... Osteopal V is used for the augmentation ... zirconium dioxide is included in the cement ...
Leadpoint Micro-Electrode Recording...
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
Stereoplan, a three-dimensional software package for planning stereotactic procedures. Stereoplan provides diverse compatibility by supporting both the Radionics CRW frame and the Leksell G frame....
Medicine Products: